# Understanding barriers to single-dose intravesical chemotherapy in non-muscle invasive bladder cancer

> **NIH NIH K23** · INDIANA UNIVERSITY INDIANAPOLIS · 2020 · $142,327

## Abstract

Project Summary/Abstract
Randomized trials utilizing a single dose of intraoperative intravesical chemotherapy following transurethral
bladder tumor resection have consistently demonstrated a reduction in bladder cancer recurrences. However,
existing data suggests intraoperative intravesical chemotherapy is used infrequently, sometimes occurs in the
wrong patients, and occurs only in a minority of cases. In this context, the candidate (Dr. Kelly Clinton Cary)
seeks to determine the barriers to intraoperative intravesical chemotherapy and how to effectively develop and
implement interventions to increase translation of this best available evidence into clinical practice. During the
period of support, he will pursue additional didactic instruction in several disciplines, including graduate-level
courses in qualitative research methods and implementation science, as well as conjoint analysis. He will also
have ample opportunities for mentored, project-based learning, including the hands-on application of cognitive
task analysis interview techniques, advanced statistical modeling with conjoint analysis, and implementation
strategy design. The research plan has three specific aims: Aim 1. To determine the barriers and facilitators to
intraoperative intravesical chemotherapy utilization in non-muscle invasive bladder cancer. The candidate will
conduct semi-structured interviews with key stakeholders directly or indirectly involved in the process of
delivering intraoperative intravesical chemotherapy using the interview technique of cognitive task analysis.
Key stakeholders will involve five distinct groups: 1) urologists, 2) patients, 3) pharmacists, 4) nurses, 5)
administrative leaders. He hypothesizes it will be possible to identify several barriers and facilitators through
the interview process. Aim 2. To assess the relative importance of individual barriers and facilitators to
intravesical chemotherapy utilization. The candidate will perform a conjoint analysis study using clinical
vignettes to identify which barriers are most important in utilizing intravesical chemotherapy. This analysis will
use a marketing research technique to determine which barriers and facilitators are most influential resulting in
a rating of individual barriers. He hypothesizes that not all barriers and clinical factors are considered equally
important or influential. Aim 3. To develop intervention and implementation strategies to address the most
important barriers to intravesical chemotherapy utilization. Using implementation science methods,
intervention(s) and implementation strategies targeting the most important barriers and facilitators will be
developed and iteratively improved using key stakeholders' input. He hypothesizes that well designed
intervention and implementation strategies tailored to important barriers and facilitators with iterative input from
key stakeholders can be developed to improve the delivery of evidence-based medicine. Completion of the
prop...

## Key facts

- **NIH application ID:** 9987568
- **Project number:** 5K23CA212272-05
- **Recipient organization:** INDIANA UNIVERSITY INDIANAPOLIS
- **Principal Investigator:** Kelly Clinton Cary
- **Activity code:** K23 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $142,327
- **Award type:** 5
- **Project period:** 2016-09-14 → 2021-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9987568

## Citation

> US National Institutes of Health, RePORTER application 9987568, Understanding barriers to single-dose intravesical chemotherapy in non-muscle invasive bladder cancer (5K23CA212272-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9987568. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*